Enabling precision medicine
Olink Proteomics at a glance
Olink® develops and markets its unique technology for protein analysis in human protein biomarker research. Olink’s proprietary Proximity Extension Assay (“PEA”) technology enables researchers to analyze large numbers of proteins with exceptional data quality and minimal sample consumption. This enables research previously not possible while also lowering costs. The technology drives precision medicine by improving the understanding of the interaction of proteins and human disease.
- Location
- Sweden
- Website
- https://www.olink.com
- Investment theme
- Changing Demographics
- Contact
- tommi.unkuri@summaequity.com
- SDG alignments
- 3
- Year sold
- 2024
What are the challenges Olink addresses
-
80%
of patients receive no benefit from treatment with top 10 best-selling drugs in the world
-
9.2%
of OECD GDP is spent on healthcare
How does Olink help?
Reality today
Scientists do not fully understand the complex biology of most human diseases – in particular the role of proteins – limiting their ability to develop effective therapeutics and delivering precision treatment.
Olink approach
Olink’s proprietary Proximity Extension Assay (PEA) technology enables researchers to efficiently analyze large numbers of proteins with high throughput analysis, advancing our understanding of protein interactions in human diseases and our ability to develop new therapies.
Aspirational future
Deeper understanding of human biology and disease allows us to develop and deliver the most effective treatments for patients.
Who is impacted?
Researchers are impacted directly through more effective tools to understand human biology. Patients are impacted indirectly by scientific breakthroughs in treatments resulting from research using Olink technology.
Contribution
By providing a truly unique technology to the market, Olink makes a major contribution to the research enabling advancements in precision medicine.
Risks
Olink’s impact depends in part on how its customers in academia and biopharma choose to use its tools. The company benefits from engaging with customers to help ensure that the research it enables translates into treatment innovations and, eventually, patient outcomes.